TL;DR
Researchers have determined the high-resolution structures of α-synuclein filaments from brains affected by Parkinson's disease (PD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB). They discovered that these diseases share a common "Lewy fold" structure, distinct from the filaments found in multiple system atrophy (MSA), suggesting a shared molecular basis for these neurodegenerative conditions.
What Problem Does This Paper Address?
Parkinson's disease (PD) and related disorders like dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) are characterized by the accumulation of misfolded α-synuclein protein in the brain, forming structures called Lewy bodies and Lewy neurites. While it's known that these protein aggregates are central to the pathology, the precise three-dimensional structure of these filaments in different disease states has remained largely unknown. Understanding these structures is crucial because different protein folding patterns (conformers) can lead to distinct disease mechanisms and potentially different therapeutic targets. Previous work had characterized α-synuclein filaments from multiple system atrophy (MSA), another synucleinopathy, revealing two distinct filament types, each composed of two protofilaments. This study aimed to resolve the structures of α-synuclein filaments from PD, PDD, and DLB to see if they were similar to MSA or if they represented a unique structural class, thereby shedding light on the molecular underpinnings of these related diseases.
Methods
The researchers employed cryo-electron microscopy (cryo-EM) to determine the atomic structures of α-synuclein filaments. This technique involves flash-freezing samples and imaging them with an electron microscope, allowing for the reconstruction of 3D structures at near-atomic resolution.
Key steps included:
- Extraction of Sarkosyl-insoluble material: This process isolates the aggregated α-synuclein filaments from brain tissue.
- Helical Reconstruction: Since the filaments are essentially long, repeating tubes, a helical reconstruction method was used to combine information from many images to build a high-resolution 3D model.
- Model Building and Refinement: Atomic models of the α-synuclein protein were built into the cryo-EM density maps and then refined to achieve the best fit.
The study also utilized negative-stain electron microscopy for initial visualization and immunoblotting with specific antibodies to confirm the presence and size of α-synuclein in the extracted samples.
Datasets
The study used brain tissue samples from individuals diagnosed with:
- Parkinson's disease (PD)
- Parkinson's disease dementia (PDD) - two cases (PDD1, PDD2)
- Dementia with Lewy bodies (DLB) - three cases (DLB1, DLB2, DLB3)
These samples were obtained from the cingulate cortex and frontal cortex of these individuals. No new benchmarks or datasets were introduced; the study focused on analyzing existing biological samples.
Key Insights and Ideas
- A Unified "Lewy Fold": A major finding is that α-synuclein filaments from PD, PDD, and DLB all adopt a remarkably similar, single protofilament structure, which the authors term the "Lewy fold." This suggests a common molecular mechanism underlying these diseases.
- Distinct from MSA: The Lewy fold is structurally distinct from the two types of α-synuclein filament folds previously identified in multiple system atrophy (MSA). This highlights that different neurodegenerative synucleinopathies can be driven by distinct protein conformations.
- Implications for Disease Continuum: The shared Lewy fold structure supports the idea that PD, PDD, and DLB are closely related and may exist on a disease continuum, differing primarily in the timing and extent of cognitive impairment.
- Structural Basis for Cofactor Interaction: The cryo-EM structures revealed densities that likely correspond to unidentified cofactors, which may play a crucial role in the formation and stabilization of the Lewy fold.
Key Results
- The cryo-EM analysis yielded high-resolution structures (down to 2.2 Å) of α-synuclein filaments from PD, PDD, and DLB brains.
- These filaments are composed of a single protofilament, forming the "Lewy fold."
- The Lewy fold is characterized by a right-handed twist, contrasting with the left-handed twist observed in MSA filaments.
- The core of the Lewy fold is formed by residues 31-100 of α-synuclein, arranged in a specific β-strand structure.
- The study identified potential binding sites for non-proteinaceous cofactors within the Lewy fold structure.
Limitations and Future Work
- Untwisted Filaments: The study focused on twisted filaments for structural determination, as these are amenable to helical reconstruction. While untwisted filaments were observed and their projections resembled the Lewy fold, their exact structures were not fully resolved. It remains to be investigated if minority folds exist in untwisted filaments or if cryo-EM preparation itself can lead to untwisting.
- Cofactor Identification: The densities attributed to cofactors could not be definitively identified. Future work could focus on identifying these cofactors and understanding their role in filament formation and disease.
- Post-Translational Modifications: The study notes that the Lewy fold structure does not show evidence of phosphorylation at Tyr39, which has been observed in some in vitro assembled filaments. Further research is needed to understand the role of post-translational modifications in dictating α-synuclein filament structures in vivo.
- Recombinant vs. Brain Filaments: The authors acknowledge that filaments assembled from recombinant α-synuclein in vitro have not yet fully replicated the Lewy or MSA folds found in human brains. Developing methods to assemble recombinant α-synuclein into these specific disease-associated folds is a key future direction. This would be crucial for understanding the mechanisms of fold formation and for developing targeted therapies.
- Animal Models: The development of animal models that recapitulate the specific α-synuclein filament structures found in human brain diseases is also highlighted as an important future goal.
Summary updated